For research use only
| Cat No. | ABC-TC0459 |
| Product Type | Human Melanoma Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Pleural Epithelioid Mesothelioma |
| Product Code | IST-MES2; IST-MES-2; ISTMES2; IstMes2 |
IST MES2 mesothelioma cells express CD24, ABCG2, OCT4, grow as adherent or spherical clusters, used in drug resistance and metastasis research.
IST MES2 is a human malignant pleural mesothelioma cell line established from the pleural effusion of a 71-year-old, Caucasian male patient with biphasic mesothelioma (malignant pleural mesothelioma (MPM)). These adherent cells exhibit spindle-shaped to polygonal morphology, reflecting both epithelial and sarcomatoid features of biphasic tumors. IST-MES2 expresses mesothelial markers such as calretinin, WT-1, and cytokeratin, and lacks epithelial growth factor receptor (EGFR) amplification. In addition, these cells are capable to express stemness markers such as CD24, ABCG2 and OCT4 that can be utilized in the research for mechanisms of MPM drug resistance and metastasis. The cell line displays complex chromosomal alterations, including losses in chromosome arms 9p and 22q, commonly associated with mesothelioma pathogenesis. IST-MES2 is tumorigenic in immunodeficient mice, forming invasive pleural tumors. While primarily localized, it exhibits limited metastatic spread under experimental conditions.
| Product Code | IST-MES2; IST-MES-2; ISTMES2; IstMes2 |
| Species | Human |
| Cat.No | ABC-TC0459 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Pleural Epithelioid Mesothelioma |
| Biosafety Level | 2 |
| Storage | Liquid Nitrogen |
| Product Type | Human Melanoma Cell Lines |
IST-MES2 is an established in vitro model for studying malignant pleural mesothelioma biology, particularly biphasic tumor subtypes. It is widely used in research on mesothelioma pathogenesis, asbestos-related oncogenesis, and therapeutic resistance. The line supports preclinical screening of chemotherapeutics, targeted therapies, and immunotherapy candidates. IST-MES2 also facilitates investigations into mesothelial cell signaling, gene expression, and tumor invasion mechanisms.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
